Biogenic Amine Cellular Source: Mast cells, basophils Physiological response: 1. vasodilation 2. increased vascular permeability 3. pain Mechanism: Activation of GPCRs Pharmacology: Antihistamines (H1 antagonists)
Histamine
Peptide Cellular Source: Endothelial cells Physiological response: 1. vasodilation 2. increased microvessel permeability 3. pain Mechanism: activation of GPCRs Pharmacology: receptor antagonists being tested
Bradykinin
Plasma proteins
Cellular Source: synthesized by liver, circulates in blood
Physiological response:
1. Chemotaxis: recruitment of inflammatory cells to site of injury
2. promote release of mediators from neutrophil
3. increase vascular permeability
4. excessive activation may contribute to tissue injury
Mechanism: complement protein complexes cause osmotic lysis, activation of GPCRs
Pharmacology: Eculizumab, APT070
Complement
Plasma protein
Cellular Source: produced in liver in response to cytokines, adipocytes
Physiological Response:
1. “acute phase reactant”
2. activates complement cascade
3. mediates phagocytosis
4. “marker of inflammation”
Mechanism: binds to phospholipids in bacteria and damaged cells, may be specific receptors in macrophages
Pharmacology: elevated CRP may be associated with increased risk of diabetes, hypertension and cardiovascular disease, statins may help
C-Reactive Protein
Secreted proteins (IL-a, IL-B, TNF-a)
Cellular source: nearly all inflammatory cells
Physiological response:
1. TNF-a: acute phase reaction, fever, sepsis
2. IL-1: acute phase reaction, fibroblast and lymphocyte proliferation, fever
Mechanism: bind to specific receptor proteins to induce gene expression in number of proteins via activation of NFkB and AP-1 –> increase COX and lipoxygenases, increase adhesion molecule expression, induce collagenase (fibrosis)
Pharmacology: etanercept, Infliximab
Cytokines
Purine Nucleotide
Cellular source: all cells
Physiological response:
1. Increased extracellularly during injury - anti-inflammatory
2. Inhibit cytokine action
Mechanism: activation of GPCRs
Pharmacology: Adenosine A2 agonists, Methotrexate, Folic acid antagonist
Adenosine
Family of Proteins
Cellular source: endothelial cells, platelets, leukocytes
Physiological response:
1. Leukocyte adhesion to endothelium
2. Endothelial adhesion molecules recruit activated platelets
Mechanism: contact molecules, calcium dependent
Pharmacology: Abciximab
Cell Adhesion Molecule
Lipid Mediator Cellular source: virtually all cells Physiological response: 1. Vasodilation/vasoconstriction 2. pain 3. fever 4. platelet aggregation (via thromboxanes) Pharmacology: NSAIDS
Prostaglandin
Lipid Mediator
Cellular source: macrophages, neutrophils
Physiological response:
1. Increased vascular permeability
2. Bronchoconstriction
Mechanism: activation of GPCRs
Pharmacology: Zileuton - 5 lipoxygenase inhibitor
Zafirlukast - cys-leukotriene receptor antagonist
Leukotriene
Lipid Mediator Cellular source: adrenal cortex Physiological Response: 1. inhibition of cytokines 2. inhibition of phospholipase A2 3. inhibition of COX2 4. inhibition of cell adhesion molecules Mechanism: activation of nuclear receptors Pharmacology: steroids
Glucocorticoid
Physiological response:
Histamine
Physiological response:
Bradykinin
Physiological response:
Complement
Physiological Response:
C-Reative Protein
Physiological response:
Cytokines
Physiological response:
Adenosine
Physiological response:
Cell Adhesion Molecules
Physiological response:
Prostaglandins
Physiological response:
Leukotrienes
Physiological Response:
Glucocorticoids
Exists as two isoforms, oxygenate and cyclize the precursor fatty acid to form cyclic endoperoxide (PGG), peroxidase activity converts PGG2 to PGH2
Inhibited by Aspirin
Cyclooxygenase
Constitutive
COX-1
Larger active site, inducible
COX-2
Most abundant precursor of eicosanoids, concentration in cells is low, Found esterified to membrane phospholipids
Arachidonic Acid